TW201302736A - 組織蛋白酶（Ｃａｔｈｅｐｓｉｎ）Ｃ抑制劑 - Google Patents

組織蛋白酶（Ｃａｔｈｅｐｓｉｎ）Ｃ抑制劑 Download PDF

Info

Publication number
TW201302736A
TW201302736A TW101104141A TW101104141A TW201302736A TW 201302736 A TW201302736 A TW 201302736A TW 101104141 A TW101104141 A TW 101104141A TW 101104141 A TW101104141 A TW 101104141A TW 201302736 A TW201302736 A TW 201302736A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
aryl
compound
cycloalkyl
Prior art date
Application number
TW101104141A
Other languages
English (en)
Chinese (zh)
Inventor
Christopher E Neipp
Michael R Palovich
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46638952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201302736(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of TW201302736A publication Critical patent/TW201302736A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW101104141A 2011-02-11 2012-02-09 組織蛋白酶（Ｃａｔｈｅｐｓｉｎ）Ｃ抑制劑 TW201302736A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161441840P 2011-02-11 2011-02-11

Publications (1)

Publication Number Publication Date
TW201302736A true TW201302736A (zh) 2013-01-16

Family

ID=46638952

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101104141A TW201302736A (zh) 2011-02-11 2012-02-09 組織蛋白酶（Ｃａｔｈｅｐｓｉｎ）Ｃ抑制劑

Country Status (24)

Country Link
US (2) US8841463B2 (enExample)
EP (1) EP2672821B9 (enExample)
JP (1) JP5931929B2 (enExample)
KR (1) KR20140048857A (enExample)
CN (1) CN103491777B (enExample)
AR (1) AR085163A1 (enExample)
AU (1) AU2012214405B2 (enExample)
BR (1) BR112013020510A2 (enExample)
CA (1) CA2827157A1 (enExample)
CL (1) CL2013002325A1 (enExample)
CO (1) CO6741219A2 (enExample)
DO (1) DOP2013000182A (enExample)
EA (1) EA023168B1 (enExample)
ES (1) ES2583091T3 (enExample)
IL (1) IL227814A0 (enExample)
MA (1) MA34961B1 (enExample)
MX (1) MX2013009279A (enExample)
PE (1) PE20140999A1 (enExample)
PH (1) PH12013501665A1 (enExample)
SG (1) SG192669A1 (enExample)
TW (1) TW201302736A (enExample)
UY (1) UY33905A (enExample)
WO (1) WO2012109415A1 (enExample)
ZA (1) ZA201306074B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
NO2699580T3 (enExample) 2014-01-24 2018-02-24
CA3013850C (en) * 2016-02-12 2024-01-30 Pharmaxis Ltd. Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
AU2023296161A1 (en) 2022-06-13 2025-01-02 Alivexis, Inc. Azacycloalkyl carbonyl cyclic amine compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
CN1240355A (zh) * 1996-05-01 2000-01-05 伊莱利利公司 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途
US6214799B1 (en) 1996-05-14 2001-04-10 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US20020107266A1 (en) 2000-12-12 2002-08-08 Marguerita Lim-Wilby Compounds, compositions and methods for treatment of parasitic infections
EP2195321B1 (en) * 2007-04-12 2016-10-19 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives as inhibitors of protein kinase c
BRPI1015540A2 (pt) * 2009-05-07 2019-09-24 Astrazeneca Ab ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
UY32827A (es) * 2009-08-12 2011-02-28 Glaxo Group Ltd Inhibidores de catepsina c
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors

Also Published As

Publication number Publication date
KR20140048857A (ko) 2014-04-24
EP2672821B1 (en) 2016-04-20
DOP2013000182A (es) 2014-03-16
ZA201306074B (en) 2014-04-30
AU2012214405B2 (en) 2015-07-23
NZ614540A (en) 2015-03-27
WO2012109415A1 (en) 2012-08-16
SG192669A1 (en) 2013-09-30
EP2672821A4 (en) 2014-08-06
US8841463B2 (en) 2014-09-23
IL227814A0 (en) 2013-09-30
EA201391155A1 (ru) 2014-01-30
ES2583091T3 (es) 2016-09-19
JP2014506577A (ja) 2014-03-17
EP2672821B9 (en) 2016-11-23
PH12013501665A1 (en) 2019-07-17
AR085163A1 (es) 2013-09-11
MA34961B1 (fr) 2014-03-01
US20130324584A1 (en) 2013-12-05
MX2013009279A (es) 2013-10-28
CL2013002325A1 (es) 2014-01-03
US9187461B2 (en) 2015-11-17
EP2672821A1 (en) 2013-12-18
BR112013020510A2 (pt) 2016-07-12
UY33905A (es) 2012-08-31
CN103491777B (zh) 2015-05-06
AU2012214405A1 (en) 2013-04-18
US20140364476A1 (en) 2014-12-11
EA023168B1 (ru) 2016-04-29
PE20140999A1 (es) 2014-09-11
CN103491777A (zh) 2014-01-01
CA2827157A1 (en) 2012-08-16
CO6741219A2 (es) 2013-08-30
JP5931929B2 (ja) 2016-06-08

Similar Documents

Publication Publication Date Title
ES2401812T3 (es) Derivados de triazolil tropano como moduladores de CCR5
AU2007330478B2 (en) Crystalline forms of ( 3 S ) -3- [N- (N' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluorophenoxy) -4-oxopentanoic acid
JP2017128605A (ja) 抗ウイルス化合物の固体形態
CA2895448A1 (en) Autotaxin inhibitors
JP6272626B2 (ja) カンナビノイド受容体媒介性化合物
CN105612149A (zh) 作为二肽基肽酶i抑制剂的肽基腈化合物
WO2014091443A1 (en) Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
CZ20022096A3 (cs) Kvarterní amoniová sloučenina pro použití při léčení a/nebo prevenci kašle u teplokrevného živočicha a farmaceutický prostředek ji obsahující
US9187461B2 (en) Cathepsin C inhibitors
CZ20022095A3 (cs) Cyklická kvarterní amoniová sloučenina pro použití při léčbě a/nebo prevenci kašle u teplokrevného živočicha a farmaceutický prostředek ji obsahující
TWI870362B (zh) 一類新型二肽類化合物及用途
CN106660968A (zh) 吡唑衍生物及其作为大麻素受体介体的用途
CN103420981A (zh) 含有取代吡咯烷基的硫代吗啉类化合物
JP6906444B2 (ja) 疾患および状態を処置するための組成物および方法
WO2019001307A1 (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
NZ614540B2 (en) Cathepsin c inhibitors
KR20120061870A (ko) 카텝신 ｃ 억제제
WO2012112733A1 (en) Cathepsin c inhibitors
JP2831952B2 (ja) Ｎ−（シクロアルキル）アルキルアゼピン誘導体の用途
RU2603962C2 (ru) Новый класс селективных агонистов соматостатиновых рецепторов
TW202411231A (zh) 用作泛素-特異性蛋白酶抑制劑的取代嘌呤酮衍生物
EP4357335A1 (en) Azabicyclo[3.1.0]hexane compound
CN107304180B (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
US20250179118A1 (en) Novel dipeptide compounds and uses thereof
WO2001010844A1 (fr) DERIVES D'ACIDE φ-AMINO-α-HYDROXYCARBOXYLIQUE POSSEDANT UN ANTAGONISME αvβ3 D'INTEGRINE